Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies.

Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.

Traded as:           TSX: ONC, NASDAQ: ONCY

Industry:              Biopharmaceutical

Founded:             1998 Calgary, Alberta, Canada

Headquarters:    Calgary, Alberta, Canada

Products              REOLYSIN, a first-in-class intravenously delivered immuno-oncolytic virus (IOV) for the treatment of solid tumors and hematological malignancies.

Website:              www.oncolyticsbiotech.com